Generic

Pharmexcil, the sector's leading export body, said it is prudent to stay prepared for any future policy shift and build risk-mitigation strategies.

A year of hits and misses for the Indian pharma sector

Even as pharma exports grew in terms of volumes and value, the cloud of inadequate hygiene and safety in some pharma companies continued to hang over the industry, forcing the government to put in place more stringent inspections and processes.

Glenmark launches generic version of diuretic with $16.5-million market

Glenmark Pharmaceuticals will launch single-dose and multi-dose vials of Bumetanide injection USP, the company has said

Glenmark gets USFDA nod for generic acne treatment gel

The approval granted to Glenmark Pharmaceuticals Inc by the US Food and Drug Administration is for Adapalene and Benzoyl Peroxide Gel, 0.1 per cent/2.5 per cent, which is the the generic version of Epiduo gel, 0.1 per cent/2.5 per cent of of Galderma Laboratories LP, the company said in a statement.

Strides Shasun receives USFDA tentative nod for Fingolimod

Pharma firm Strides Shasun Limited today announced that its subsidiary Strides Pharma Global Pte Limited, Singapore has received tentative approval from the United States Food & Drug Administration (USFDA) for its Para IV filing of Fingolimod capsules.

Trump intervention in pharma may affect Indian suppliers: PwC

Speaking to CNBC-TV18, Sujay Shetty, Pharma Head at consultancy giant PwC India, said that the new US regime is likely to take up cudgels on behalf of American drug companies.

Dr Reddy's launches generic Lamotrigine tablets in US

The company's tablets are in the strengths of 25 mg, 50 mg, 100 mg and 200 mg, Dr Reddy's Laboratories said in a filing to BSE.

Pharmaceutical industry growth to remain moderate, says Icra

Growth of the domestic pharmaceutical industry is likely to remain moderate due to factors like slowdown in the US market, increased competition and generic adoption reaching saturation levels, rating agency ICRA said today.

We are planning 6-8 new launches this fiscal yr: Alembic Pharma

Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

Hikma to buy Boehringer's US generics unit for $2.65 bn

Hikma said it will pay about USD 1.18 billion in cash and issue 40 million new Hikma shares, or about 16.71 percent of its issued share capital, for Boehringer's Roxane Laboratories Inc and Boehringer Ingelheim Roxane Inc on closing of the deal.

Hope for Hepatitis C-affected Indians

US-based Gilead's revoluntionary drug Sofosbuvir will finally be available in India at a fraction of its original cost, thanks to licensing agreements with seven generic companies.

'Ranbaxy's Nexium generic loss may up Cipla's EPS 3-5%'

The US FDA‘s decision to revoke the 180-day exclusivity cover extended to Indian firm Ranbaxy to sell a generic version of the world‘s second-largest selling drug esomeprazole is likely to help rival Cipla, according to Vivek Kumar, research analyst, SBICap Securities.

Ranbaxy forfeits 180 days exclusivity for stomach drugs

Drug major Ranbaxy today said that the US health regulator has "determined" that the Indian drug manufacturer has forfeited its 180 days exclusivity for stomach and esophagus problems treatment tablets.

Panacea enters into alliance with Canada based Apotex Inc

In addition to upfront and milestone research fee payments from Apotex, the company shall receive a share of development cost and profit.

Strides Arcolab up 3%, Macquarie says dividend to drive it

During the last earnings call, Strides Arcolab had highlighted that from USD 390 million of receivables from Mylan, it expects contingent holdback (of USD 250 million) to get released in Q2 FY15. With 20 days left for Q2FY15 end, dividend could be a near-term catalyst.

Cipla at new high, up 8%; respiratory drug launch in UK key

Though analysts are impressed by its earlier- than-expected launch, most of them have not yet upgraded Cipla yet. Credit Suisse maintains a neutral rating on it stating base case is already priced in. According to the brokerage, Germany and Sweden are small markets but the launch signifies approval in the UK could be expected by FY15-end.

Ranbaxy, Teva settle US anti-trust probe for $3,00,000

The rival drugmakers had entered into a profit-sharing deal barring one from challenging the other's right to sell generic drugs for an exclusive period.

Q2 nos drive Aurobindo Pharma to 34-month high, up 10%

The drug company's consolidated net profit rose 5.7 percent to Rs 235 crore for the second quarter ended September 30, 2013 from Rs 222.4 crore year-on-year.

Lupin to rely on Antara sales to rebuild brand: MD

After receiving the USFDA nod for its supplemental new drug application for Antara capsules on Tuesday, Lupin will now focus on building back its brand by gaining its lost market share.

Expect $100m revenue via Elores by FY18: Venus Remedies

In an interview to CNBC-TV18, Dheeraj Aggarwal, CFO, Venus Remedies spoke about revenue prospects of Elores, for which the company recently won patent from Japan.

Glenmark Pharma Q4 beats street, net up 11% to Rs 167 cr

Glenmark Pharma beat street expectation on Tuesday with a consolidated net profit of Rs 167 crore in Jan-March, up 11 percent from a year ago. Net sales gained 25 percent to Rs 1,335 crore.

Contraceptives basket can fetch $150m from US sales: Lupin

Pharma major Lupin expects sales in the US to touch at least USD 150 million per quarter going ahead, S Ramesh, CFO, said on Tuesday.

Ranbaxy rises after Nomura upgrades stock to 'buy'

Ranbaxy Laboratories shares gained 2 percent on Monday morning after Nomura Financial Advisory and Securities India upgraded the pharma major to "buy" from "neutral." The brokerage also raised its target price on the stock to Rs 475 from Rs 415.

Enaltec bets on niche APIs to earn Rs 400cr by 2016

Entrepreneurship is not for the faint hearted and it is about taking a leap of faith. This is what drove three young men to leave their high profile jobs to start up on their own in the USD 80 billion healthcare market in India.

Dr Reddy's launches oncology injection in US

Generics drugs maker Dr Reddy's Laboratories on Tuesday said it has launched Zoledronic Acid injection 4mg/5ml in the US market following approval by the US Food and Drugs Administration.